36 results about "Galantamin" patented technology

Ethamine compound is obtained by condensing starting materials of 6-bromoisovanillin and tyramine under catalysis of NaBH4 in carbinol. In formylation of ethamine compound, aminic acid and formaldehyde of same amount are used to produce formyl compound, with temperature between 90 DEG C. and 110 DEG C., 8h. Racemic bromonarwedine is obtain by oxidation and cyclization of the formyl compound. Racemic narwedine is obtained by reduction reaction under catalysis of NaCO2H, PPh3, Pd(OAc)2. Racemic narwedine is transformed into (-)-narwedine by a process of crystal inoculation. (-)-narwedine is reduced into unsaturated ketone by (-)-N-methyl ephedrine as chiral reagent, whereby optically active alcohol is obtained, and (-)-galanthamine is also obtained.

The invention discloses a process of extracting dihydrogalanthamine from Lycoris radiata plant, which in detail relates to a method for separating dihydrogalanthamine exquisite from alkaloid extracted from Lycoris radiata plant, and it is a recombined method of enzyme technology and chromatography. It comprises process and condition of extraction and separation of coarse lycorine, then extracting filtering liquid of coarse lycorine, condensing, preparing column material, loading column, eluting, condensing, recrystallizing and getting dihydrogalanthamine with purity of over 99%. The invention is different from method using organic solvent for dihydrogalanthamine extraction, and it can obtain coarse lycorine, coarse galantamin and dihydrogalanthamine with purity over 99%.

The invention provides an amorphous galanthamine dihydroxy naphthoate compound and a preparation method thereof, the compound has low solubility, good stability and high safety, and a pharmaceutical preparation prepared by using the compound as an active component has good dissolution performance. In addition, the galanthamine dihydroxy naphthoate provided by the invention is simple in preparationprocess, high in product yield, high in purity and suitable for industrial production.

A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt of thereof is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

A skin patch which improves symptoms of ashronesia, delusion and myasthenia caused by cholinergic deficit is composed of an antiseizing layer, a medicine storing layer and a back lining layer, wherein the medicine storing layer comprises medicine, dissolvent and pressure-sensitive adhesive. The invention is characterized in that the medicine is galantamin or hydrobromate thereof. The galantamin or hydrobromate thereof is 0.007mg-10mg/cm<2>, and the medication area is 2.5-70cm<2>. The pressure-sensitive adhesive is selected from polyisobutene pressure-sensitive adhesive, emulsion and dissolvent type acrylate. When the pressure-sensitive adhesive is polyisobutene, the medicine storing layer is composed of medicine, dissolvent, pressure-sensitive adhesive, thickening agent, anti-oxidant and transdermal promoter. When the pressure-sensitive adhesive is emulsion type acrylate, the medicine storing layer is composed of medicine, dissolvent, pressure-sensitive adhesive, thickening agent and concentrated ammonia liquor. When the pressure-sensitive adhesive is dissolvent type acrylate, the medicine storing layer is composed of medicine, dissolvent, and pressure-sensitive adhesive. The skin patch of the invention can effectively treat the symptoms of ashronesia, delusion and myasthenia caused by cholinergic deficit, increase the life quality of patient and alleviate the burden of kin and society.

The invention discloses a galantamin hydrobromide producing method for treating senile dementia, which comprises the following steps: adopting the method of enzyme reaction, continuous kinesis flow upstream extracting and column chromatography to extract galantamin with purity of 99% from Amaryllidaceae plant; Using galantamin with purity of 99 percent as raw material; obtaining galantamin hydrobromide with purity of 98.5. percent. The invention discloses an extracting galantamin of purity at 99% process flow and technological condition from Amaryllidaceae plant, which adapts for industrialization production.

The invention discloses a novel method for preparing galanthamine sustained-release microspheres, and particularly relates to a method for preparing galanthamine microspheres by adopting a novel solvent propylene carbonate. Galanthamine pamoate is used as a raw material, and the galanthamine sustained-release microspheres prepared by using an emulsification-solvent volatilization method have the advantages of high encapsulation efficiency, high product yield, less residual solvent and the like.

The invention provides a method for increasing the content of alkaloid in lycoris radiata through an exogenous substance, and relates to the field of plant growth and secondary metabolite accumulation regulation. According to the method for increasing the content of the alkaloid in the lycoris radiata through the exogenous substance, 3-month-to-one-year-old tissue culture seedlings of the lycoris radiata are treated through the exogenous substance 4 '-O-methyl norlinaldine and/or jasmonic acid methyl ester, so that the content of three alkaloids, that is, galanthamine, lycorine and lycorine which have important medicinal values in the lycoris radiata are effectively increased.

A process for separating high-purity galantamin from the coarse extract of short-tube lycoris by counter-current chromatography includes such steps as preparing two-phase solvent system from 2,3,044 of paraffin, halohydrocarbon, emtrol, lipoketone, lipoester, ether, buffering liquid of inorganic salt and water, waving, laying aside for layering, dissolving the coarse extract of short-tube lycoris, and separating. Its advantages are high separating capacity and recovery rate, and less solvent consumption.

This invention is related to an oral pharmaceutical composition that contains a cholinergic agent, a natural plant alkaloid in particular, selected from the group of lobeline, anabasine, cytisine, galantamine or their acceptable salts, in the form of tablets and capsules. The excipients of the developed oral composition include cellulose powder, calcium sulphate, silica colloidal and magnesium stearate, the total content of cellulose powder and calcium sulphate dihydrate being from 64,5 to 97,5 % of the mass of the dosage form and at least 90% of the alkaloid particles being < 100um. The oral composition contains also at least one biologically active amino acid selected from: L-carnitine, tryptophan or a combination of them. The oral composition according to this invention achieves uniform distribution of the active substance in the composition, as well as stability of the composition due to the included excipients selected so as to react to a minimum with the alkaloid to form the qualitative and quantitative related substances admissible for the pharmaceutical composition. The composition according to this invention is applicable in the treatment of dependency and addiction to nicotine, tobacco products and alcohol.

The invention relates to a purification production process for galanthamine. According to the purification production process provided by the invention, galanthamine is purified from lycoris radiata plants; crude extraction and fine extraction are mainly included in the process; used main raw materials comprise lycoris radiata, methanol, chloroform, dichloromethane, chromatographic silica gel, absolute ethyl alcohol and hydrobromic acid; only equipment such as an extraction kettle and a concentration kettle is needed; and thus, the raw materials are convenient to obtain, equipment investment is low, operation is convenient, separation and extraction effect on galanthamine is good, the purity of an extracted product is high, production cost is low, and the process is suitable for industrial and large-scale production.

The invention provides an ointment capable of effectively treating facial paralysis and a preparation method thereof. The ointment comprises the following components: hexadecanol, glycerin monostearate, octadecanoic acid, methyl silicone oil, liquid paraffin, glycerol, ethylhexyl p-hydroxybenzoate, Tween 80, galanthamine injection and laurocapram. After being prepared, the ointment is applied to the face and comes into full contact with and is fully absorbed by acupoints and local neuromuscular junction parts on the face through massaging, so that the aims of interacting and complementing each other can be achieved, thus giving play to the two advantages of strengthening the body resistance and eliminating evil. The ointment has the characteristics of good curative effects, high cure rate, safety in use and no toxic or side effect.

The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a galanthamine intermediate compound V. According to the invention, 4-(2-(methylamino)ethyl)phenyl acetate,paraformaldehyde and 1,3-benzodioxole are used as raw materials to synthesize the novel intermediate compound V. The invention also provides a novel method for synthesizing galanthamine by using the intermediate. According to the method, use of dangerous chemical reagents is avoided, the synthesized intermediate does not generate new impurities, a green catalyst is used for replacing a traditionalcatalyst, a reaction is milder, economical and environment-friendly, yield is higher, and the method is suitable for industrial production.

The invention discloses a method for recovering a galantamine intermediate raw material 2-bromine-5-hydroxy-4-methoxybenzoic acid, wherein the method comprises the following scheme: layering a mixed solution of dichloromethane and water in a waste liquid, distilling and reducing a water layer, and carrying out outsourcing incineration on distillation residues as the waste liquid; and distilling out most of a solvent from a dichloromethane layer, reusing the solvent as a recovery solvent in an original galantamine intermediate process, adding a sodium hydroxide aqueous solution into distillation residues, hydrolyzing and reducing into B13, adjusting the pH value of the solution after the reaction is finished, separating out a solid to obtain a crude product B13, and carrying out a primary purification process to obtain the high-quality B13. B13-OMe is effectively reduced into B13, mother liquor is subjected to classified treatment, and the waste treatment cost is reduced.